You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
NameSalicylamide
Accession NumberDB08797
TypeSmall Molecule
GroupsApproved
DescriptionSalicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
Structure
Thumb
Synonyms
2-Carbamoylphenol
2-Carboxamidophenol
2-Hydroxybenzamide
o-hydroxybenzamide
OHB
Salicilamida
Salicylamidum
Salicylic acid amide
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
ExaprinHART Health
Green Guard Pain and Ache ReliefUnifirst First Aid Corporation
Medi First Pain ReliefUnifirst First Aid Corporation
Medi First Plus Pain ZapperUnifirst First Aid Corporation
Pain FreeAfassco Inc.
Pain RelieverAdvanced First Aid, Inc.
Pain Stopper ExtraNorth Safety Products LLC
Pain Stoppers RegularNorth Safety Products LLC
Pain TerminatorProvision Medical Products
Zee Pain AidZee Medical Inc
SaltsNot Available
Categories
UNIIEM8BM710ZC
CAS number65-45-2
WeightAverage: 137.136
Monoisotopic: 137.047678473
Chemical FormulaC7H7NO2
InChI KeySKZKKFZAGNVIMN-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
IUPAC Name
2-hydroxybenzamide
SMILES
NC(=O)C1=CC=CC=C1O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat LD50: 1890 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Salicylamide is combined with 5-androstenedione.Experimental, Illicit
AbciximabSalicylamide may increase the anticoagulant activities of Abciximab.Approved
AcebutololSalicylamide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Salicylamide.Approved
AcenocoumarolSalicylamide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salicylamide.Approved, Vet Approved
AclarubicinSalicylamide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salicylamide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.Approved
AliskirenSalicylamide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololSalicylamide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Salicylamide.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Amcinonide.Approved
AmikacinSalicylamide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideSalicylamide may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinSalicylamide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodSalicylamide may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Salicylamide is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Anisodamine.Investigational
annamycinSalicylamide may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide.Approved
Antithrombin III humanSalicylamide may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Salicylamide may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanSalicylamide may increase the anticoagulant activities of Apixaban.Approved
ApramycinSalicylamide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Salicylamide.Approved, Investigational
ArbekacinSalicylamide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinSalicylamide may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSalicylamide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololSalicylamide may decrease the antihypertensive activities of Arotinolol.Approved
AtenololSalicylamide may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide.Approved
BalsalazideSalicylamide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminSalicylamide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSalicylamide may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Salicylamide.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salicylamide.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Salicylamide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Betamethasone.Approved, Vet Approved
BetaxololSalicylamide may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Betulinic Acid.Investigational
BevantololSalicylamide may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylamide.Approved, Investigational
BisoprololSalicylamide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinSalicylamide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololSalicylamide may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylamide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Bucillamine.Investigational
BucindololSalicylamide may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide.Approved
BufuralolSalicylamide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideSalicylamide may decrease the diuretic activities of Bumetanide.Approved
BupranololSalicylamide may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salicylamide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Salicylamide.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylamide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylamide.Approved, Vet Approved, Withdrawn
CarteololSalicylamide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSalicylamide may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Celecoxib.Approved, Investigational
CeliprololSalicylamide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinSalicylamide may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylamide.Approved
CinoxacinSalicylamide may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinSalicylamide may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidSalicylamide may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salicylamide.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Salicylamide is combined with Curcumin.Investigational
CyclosporineSalicylamide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Salicylamide is combined with D-Limonene.Investigational
Dabigatran etexilateSalicylamide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSalicylamide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSalicylamide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinSalicylamide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Salicylamide is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinSalicylamide may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salicylamide.Approved
DextranSalicylamide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Salicylamide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Salicylamide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Salicylamide may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylamide.Approved, Vet Approved
DicoumarolSalicylamide may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salicylamide.Approved
DihydrostreptomycinSalicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Salicylamide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylamide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salicylamide.Approved
DoxorubicinSalicylamide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneSalicylamide may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Salicylamide is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ebselen.Investigational
Edetic AcidSalicylamide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSalicylamide may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Salicylamide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salicylamide.Approved
EnoxacinSalicylamide may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinSalicylamide may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole.Approved
EpirubicinSalicylamide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneSalicylamide may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.Approved
EquileninThe risk or severity of adverse effects can be increased when Salicylamide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Equilin.Approved
EsmololSalicylamide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone sulfate.Approved
Etacrynic acidSalicylamide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide.Approved, Investigational
Ethyl biscoumacetateSalicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Salicylamide is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Salicylamide.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylamide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Salicylamide.Vet Approved
FleroxacinSalicylamide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylamide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fludrocortisone.Approved
FluindioneSalicylamide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineSalicylamide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Salicylamide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylamide.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylamide.Approved, Nutraceutical, Vet Approved
FondaparinuxSalicylamide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSalicylamide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylamide.Approved
FramycetinSalicylamide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideSalicylamide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateSalicylamide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinSalicylamide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSalicylamide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salicylamide.Approved, Withdrawn
GemifloxacinSalicylamide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinSalicylamide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinSalicylamide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ASalicylamide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinSalicylamide may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Salicylamide is combined with HE3286.Investigational
HeparinSalicylamide may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Higenamine.Investigational
HirulogSalicylamide may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Salicylamide.Investigational
HydralazineSalicylamide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide.Approved
Hygromycin BSalicylamide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide.Approved
IdarubicinSalicylamide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxSalicylamide may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Salicylamide.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.Approved
IndenololSalicylamide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Indoprofen.Withdrawn
INNO-206Salicylamide may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Salicylamide is combined with Istaroxime.Investigational
KanamycinSalicylamide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide.Approved
LabetalolSalicylamide may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Salicylamide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Salicylamide.Approved, Investigational
LepirudinSalicylamide may increase the anticoagulant activities of Lepirudin.Approved
LevobunololSalicylamide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSalicylamide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Salicylamide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salicylamide.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Salicylamide.Approved
LomefloxacinSalicylamide may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Salicylamide.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salicylamide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Salicylamide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide.Approved
ME-609The risk or severity of adverse effects can be increased when Salicylamide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylamide.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.Approved, Vet Approved
MesalazineSalicylamide may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salicylamide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Methylprednisolone.Approved, Vet Approved
MetipranololSalicylamide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.Approved
MetoprololSalicylamide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideSalicylamide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylamide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylamide.Approved
MometasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylamide.Approved
MoxifloxacinSalicylamide may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nabumetone.Approved
NadololSalicylamide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinSalicylamide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSalicylamide may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salicylamide.Approved
Nalidixic AcidSalicylamide may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Salicylamide is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Salicylamide.Investigational
NeamineSalicylamide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinSalicylamide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinSalicylamide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide.Approved
NetilmicinSalicylamide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Nitroaspirin.Investigational
NorfloxacinSalicylamide may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinSalicylamide may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.Approved
OlsalazineSalicylamide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Salicylamide.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Orgotein.Vet Approved
OtamixabanSalicylamide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylamide.Approved
OxprenololSalicylamide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Parecoxib.Approved
ParomomycinSalicylamide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinSalicylamide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSalicylamide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololSalicylamide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateSalicylamide may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Salicylamide.Approved
PhenindioneSalicylamide may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonSalicylamide may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylamide.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.Approved, Investigational
PindololSalicylamide may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinSalicylamide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideSalicylamide may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide.Approved, Investigational
PlicamycinSalicylamide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylamide.Approved
PractololSalicylamide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salicylamide.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Salicylamide can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Propacetamol.Approved
PropranololSalicylamide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Salicylamide.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Salicylamide.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Salicylamide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Salicylamide.Vet Approved
Protein CSalicylamide may increase the anticoagulant activities of Protein C.Approved
Protein S humanSalicylamide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSalicylamide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinSalicylamide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide.Investigational
PuromycinSalicylamide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylamide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Salicylamide.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylamide.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.Experimental, Investigational
ReviparinSalicylamide may increase the anticoagulant activities of Reviparin.Approved
RibostamycinSalicylamide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.Approved, Investigational
RivaroxabanSalicylamide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinSalicylamide may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salicylamide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Salicylamide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salicylamide.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide.Approved, Investigational
SisomicinSalicylamide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolSalicylamide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CSalicylamide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinSalicylamide may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinSalicylamide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Salicylamide.Approved
SpironolactoneSalicylamide may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Salicylamide.Investigational
StreptomycinSalicylamide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinSalicylamide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineSalicylamide may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide.Approved
SulodexideSalicylamide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Salicylamide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide.Approved, Withdrawn
TacrolimusSalicylamide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Salicylamide.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salicylamide.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylamide.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.Approved, Investigational
TemafloxacinSalicylamide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Salicylamide.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylamide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylamide.Approved
TiludronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tiludronate.Approved, Vet Approved
TimololSalicylamide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tixocortol.Approved
TobramycinSalicylamide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide.Approved
TorasemideSalicylamide may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salicylamide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneSalicylamide may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Salicylamide.Approved
TrovafloxacinSalicylamide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Salicylamide.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Salicylamide is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinSalicylamide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Salicylamide.Approved
WarfarinSalicylamide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSalicylamide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Salicylamide may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salicylamide.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.Withdrawn
ZorubicinSalicylamide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Elijah J. Gold, Esther Babad, Lydia Peer, Wei K. Chang, “Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide.” U.S. Patent US4658060, issued November, 1979.

US4658060
General ReferencesNot Available
External Links
ATC CodesN02BA75N02BA05N02BA55
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.9382
Caco-2 permeable+0.6048
P-glycoprotein substrateNon-substrate0.8565
P-glycoprotein inhibitor INon-inhibitor0.9817
P-glycoprotein inhibitor IINon-inhibitor0.9948
Renal organic cation transporterNon-inhibitor0.9178
CYP450 2C9 substrateNon-substrate0.8207
CYP450 2D6 substrateNon-substrate0.6203
CYP450 3A4 substrateNon-substrate0.7067
CYP450 1A2 substrateNon-inhibitor0.7061
CYP450 2C9 inhibitorNon-inhibitor0.952
CYP450 2D6 inhibitorNon-inhibitor0.9043
CYP450 2C19 inhibitorNon-inhibitor0.8779
CYP450 3A4 inhibitorNon-inhibitor0.8828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9144
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.864
BiodegradationReady biodegradable0.7192
Rat acute toxicity2.1150 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9867
hERG inhibition (predictor II)Non-inhibitor0.9468
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142 °CPhysProp
boiling point181.5 °CPhysProp
water solubility2060 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.28HANSCH,C ET AL. (1995)
pKa8.37 (at 20 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility7.82 mg/mLALOGPS
logP0.74ALOGPS
logP1.17ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)8.21ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity37.12 m3·mol-1ChemAxon
Polarizability13.22 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylamides
Alternative Parents
Substituents
  • Salicylamide
  • Benzamide
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Primary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Comments
comments powered by Disqus
Drug created on October 08, 2010 16:10 / Updated on August 17, 2016 12:24